Oral topotecan for refractory and relapsed neuroblastoma: A retrospective analysis

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 8, 2003, Pages 601-605

  Kramer, Kim ^a   Kushner, Brian H ^b   Cheung, Nai Kong V ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

Chemotherapy; Neuroblastoma; Topotecan

Indexed keywords

ALKYLATING AGENT; ANTIIDIOTYPIC ANTIBODY; ARSENIC; ARYLBUTYRIC ACID DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MONOCLONAL ANTIBODY; REBECCAMYCIN; THIOTEPA; TOPOTECAN; VINCRISTINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CATECHOLAMINE BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; NEUROBLASTOMA; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; RETROSPECTIVE STUDIES; TOPOTECAN; TREATMENT OUTCOME;

EID: 0042570556     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200308000-00003     Document Type: Article

References (31)

1. Brodeur GM, Castleberry RP. Neuroblastoma. In Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 3d ed. Philadelphia: Lippincott-Raven; 1997:739.
2. Philip T. Overview of current treatment of neuroblastoma. Am J Pediatr Hematol Oncol. 1992;14:97-102.
3. Kinsburry WD. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem. 1991;34:98-107.
4. Hsiang YW, Liu L, Wall ME, et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 1989;49:4385-4389.
5. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1996;18:352-361.
6. Houghton PJ, Cheshire PJ, Myers L, et al. Evaluation of 9-dimethylamino-methyl-10-hydroxycamptothecin (topotecan) against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31:229-239.
7. Rowinsky EK, Verweij J. Review of phase I clinical studies with topotecan. Semin Oncol. 1997;24:S20-3-S20-10.
8. Vassal G, Pondarre C, Boland I, et al. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie. 1998;80:271-280.
9. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily oral administration of oral etoposide: A phase I trial. J Clin Oncol. 1989;7:396-401.
10. Martin M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol. 1994;12:986-991.
11. Kushner BH, Kramer K, Cheung NKV. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol. 1999;17:3221-3225.
12. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-1749.
13. Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol. 2001;19:3967-3975.
14. Schellens JH, Creemers GJ, Beinjnen JH, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer. 1996;73:1268-1271.
15. Gerrits CJ, Burris H, Schellens JH, et al. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res, 1998;4:1153-1158.
16. Creemers GJ, Gerrits CJ, Eckardt JR, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol. 1997;15:1087-1093.
17. Craig SB, Bhatt UH, Patel K. Stability and compatibility of topotecan hydrochloride for injection with common infusions and containers. J Pharm Biomedical Analysis. 1997;16:199-205.
18. Mathew P, Ribeiro RC, Sonnichsen D, et al. Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol. 1994;12:1452-1457.
19. Greco FA, Hainsworth JD. Prolonged administration of low-daily-dose etoposide: a superior dose scheduling? Cancer Chemother Pharmacol. 1994;34: S101-S104.
20. Villablanca JG, Khan AA, Avramis VI, et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol. 1995;134:894-901.
21. Cheung NKV, Kushner BH, Cheung IY, et al. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998;16:3053-3060.
22. Gerrits CJ, Schellens JH, Burris H, et al. Prolonged exposure to oral topotecan correlates between pharmacokinetics and toxicity. Proc Am Soc Clin Oncol. 1997;16:224a.
23. Drengler RL, Kuhn JG, Schaaf LJ, et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol. 1999;17:685-696.
24. de Jonge MJA, Punt CJA, Gelderblom AH, et al. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol. 1999;17:2219-2226.
25. DeCesare M, Zunino F, Pace S. Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts. Eur J Cancer. 2000;36:1558-1564.
26. Zamboni WC, Stewart CF, Thompson J, et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst. 1998;90:505-511.
27. Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailabitity of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol. 1999;43:454-460.
28. Gerrits CJ, Schellens JH, Burris H, et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res. 1999;5:3-5.
29. White SC, Cheeseman S, Thatcher N, et al. Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res. 2000;6:868-873.
30. Pratt CB, Stewart C, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol. 1994;12:539-543.
31. Kretschmar C, Kletzel M, Murray K. Upfront phase II therapy with Taxol and topotecan in untreated children (>365 days) with disseminated (INSS stage 4) neuroblastoma: A Pediatric Oncology Group (POG) study. Med Pediatr Oncol. 1995;25:243-249.